ArticleJournal of Korean medical science2026
Single-Fraction Stereotactic Radiosurgery for Benign Perioptic Meningiomas: A Strategy for Long-Term Tumor Control and Radiation-Induced Optic Neuropathy Avoidance With a 10-Year Follow-up.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLower doses of single-fraction stereotactic radiosurgery (SF-SRS) are typically prescribed for perioptic meningiomas (POMs) due to concerns about radiation-induced optic neuropathy (RION). However, comprehensive long-term follow-up data on both tumor control and RION occurrence are currently lacking. This study endeavored to formulate safe and practical strategies for the implementation of SF-SRS in POMs, utilizing extensive ten-year follow-up data.
methodsWe retrospectively analyzed patients who underwent SF-SRS for POMs (< 2 mm from the optic apparatus [OA]) and who were followed up for more than ten years at our institution. Correlations between diverse dosimetric factors irradiated to the tumor and the OA and their respective impacts on tumor control and RION were examined.
resultsThirty patients were included (a median follow-up: 152 months). A dose of 12.7 ± 3.1 Gy was delivered to the gross tumor volume of 4.8 ± 5.1 cm³ with a coverage rate of 76.7 ± 19.1%, yielding a D
conclusionInadequate tumor coverage near the OA during SF-SRS for POMs, driven by concerns about RION, resulted in a significant incidence of long-term tumor progression and subsequent visual deterioration. Clarifying the optimal dose range is crucial for achieving sustained tumor control and preventing RION following SF-SRS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.